Navigation Links
Targeted blocking of cell death prevents fatal condition septic shock

Ghent, Belgium 27 December 2011 - Researchers of VIB and UGent have discovered a new approach to preventing septic shock, an often fatal extreme inflammatory reaction of the body. It is the most frequent cause of death at intensive care departments in hospitals. In sepsis, acute inflammation is attended by low blood pressure and blood clots, causing the organs to stop working. Only recently, the Brazilian football legend Socrates, died of the consequences of this condition. In a new study in the top journal Immunity, Peter Vandenabeele and colleagues of VIB-UGent described how blocking a particular form of cell death (necroptosis) fully protects mice against this fatal inflammation.

"This research opens up new perspectives for the treatment of fatal inflammatory diseases such as sepsis," says researcher Peter Vandenabeele of VIB and UGent. "By blocking necroptosis, we have found a possibly new target for a therapy."

Sepsis and SIRS

The Ghent scientists studied the Systemic Inflammatory Response Syndrome (SIRS). This is a severe inflammatory reaction affecting the entire body. It may be caused by an infection, such as sepsis, or by physical injury such as severe burns or a serious road accident.

Role of TNF in SIRS

The cytokine tumor necrosis factor (TNF) plays a crucial role in the occurrence of SIRS. The presence of TNF may trigger the cells to cause inflammation and programmed cell death. Inflammation is a necessary response in the body generated, among other things, to prevent or restore damage when injury and infections have been sustained. Programmed cell death can occur in two ways: via apoptosis or via necroptosis. The difference between the two forms of cell death lies among other things in communication with our immune system. Necroptosis usually provokes a strong reaction by the immune system whereas apoptosis proceeds unnoticed.

RIPK: potential therapeutic target for treatment of SIRS and sepsis

Peter Vandenabeele and his colleagues Linde Duprez, Nozomi Takahashi and Anje Cauwels have discovered that in mice eliminating apoptosis did not have any impact on lethal SIRS whereas eliminating nepcroptosis afforded full protection against the condition. The scientists managed to block nepcroptosis by eliminating RIPK (Receptor-interacting serine/threonine-protein kinase) molecules. The experiments showed that RIPK plays a crucial role in SIRS and sepsis. The molecule appears to constitute a potential therapeutic target for the treatment of SIRS and sepsis. Further research should clarify the potential applications of this discovery.


Contact: Joris Gansemans
VIB (the Flanders Institute for Biotechnology)

Related biology news :

1. Targeted antibacterial proteins may offer antibiotic alternative
2. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
3. GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients
4. Targeted adalimumab treatment can optimize long-term outcomes for patients with early RA
5. Lesser-known Escherichia coli types targeted in food safety research
6. Delivering drugs to the brain: New research into targeted treatment of Alzheimers
7. New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer
8. New mechanisms of tumor resistance to targeted therapy in lung cancer are discovered
9. UC to test targeted treatment for prostate cancer
10. Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles
11. New subtype of breast cancer responds to targeted drug
Post Your Comments:
(Date:9/30/2015)... YORK , Sept. 30, 2015  The global glucose ... billion for 2015. So says a new report on the ... diabetes management segment dominate the market, followed by continuous glucose ... publisher. Kalorama reports on the market for these products in its ... ...
(Date:9/28/2015)... Sept. 28, 2015 CLEAR, the ... its expedited traveler service is coming to ... travel, bringing a frictionless experience, serious speed ... "CLEAR offers our travelers an expedited ... said Jim Smith , Executive Director, ...
(Date:9/28/2015)... According to a new market ... (Scanner & Others), Application (Access Control & Others), Industry ... Geography Global - Forecast to 2020", published by MarketsandMarkets, the ... Million by 2020, at a CAGR of 23.40% between ... data T ables and 66 Figures ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Oct. 13, 2015 Applied BioMath ( ... decision points throughout the drug invention process, announced that ... 2015 on October 20-22, 2015 in Boston ... Co-Founder, President, and CEO of Applied BioMath, will present ... research to clinical trials" on Wednesday October 21st 2015 ...
(Date:10/13/2015)... October 13, 2015      Q ... company, has entered into a strategic relationship with Wombat ... and Paris, France based strategic ... --> This collaborative arrangement gives Q BioMed ... advisory team as well as long established pharmaceutical industry ...
(Date:10/13/2015)... ... ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its Business Development Management ... Jeff Parr has spent the past decade providing quality management software and consulting services ... Sciex to name a few. He is based in Salt Lake City, a ...
(Date:10/12/2015)... THOUSAND OAKS, Calif. and BRUSSELS ... and UCB (Euronext Brussels: UCB) today presented additional findings from ... trial. 1 The findings were presented today in an ... Mineral Research (ASBMR) 2015 Annual Meeting in Seattle ... 2 --> The small exploratory sub-study ...
Breaking Biology Technology: